Company Overview
Edgewise Therapeutics, Inc. operates as a biopharmaceutical company focused on discovering, developing, and commercializing therapies designed to treat muscle disorders. This specific sector classification places the company within the broader Healthcare industry, specifically under Biotechnology, which implies a reliance on extensive research and development cycles to bring novel treatments to market. The company currently maintains a market capitalization of $3.22B and employs a workforce of 146 individuals. These valuation figures indicate that the market assigns a significant size to the entity, a metric that often diverges from traditional revenue-based scaling common in mature manufacturing sectors due to the high cost of clinical trial phases inherent in biotechnology. The substantial market cap relative to the employee count suggests high asset intensity driven by intellectual property and ongoing clinical programs rather than current operational volume.
Financial Health
The company reports a net income of $-167,795,000 for the trailing twelve months, while EBITDA stands at $-189,322,000. The gap between the reported revenue, which is not available as a specific positive figure in the current reporting, and the net income reveals a cost structure where operating expenses and clinical development costs significantly outweigh any generated sales, resulting in a loss for the period. Free cash flow is reported at $-87,337,752, which indicates that the company is burning through cash reserves to fund its operations and research initiatives rather than generating surplus liquidity. All three reported margins—gross margin, operating margin, and profit margin—are stated at 0.0%, a metric that indicates the company is not yet profitable and that all revenue generated is consumed by direct costs and operating overhead before reaching the bottom line. In terms of balance sheet strength, the company holds cash of $530.11M against total debt of $3.99M, resulting in a debt-to-equity ratio of 0.76. This specific composition of liabilities and equity suggests a conservative approach to leverage, as the debt load is minimal relative to the substantial cash on hand. The current ratio is 19.85, which indicates an extremely high level of short-term liquidity and suggests the company can easily cover its immediate financial obligations with its liquid assets. Return on Equity is -34.2% and Return on Assets is -23.0%, metrics that reveal that management is currently utilizing the company's capital base to generate negative returns due to the heavy investment in development before product approval.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -12.84. The difference between these two metrics implies that the market is pricing in future earnings expectations that have not yet materialized in historical financial statements, often seen in pre-revenue or pre-profit biotechnology firms. The price-to-book ratio is 6.11, which indicates that the market values the company at a significant premium over its net asset book value, reflecting the high potential value of its intellectual property and pipeline assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -14.25, suggest that traditional multiple-based valuation models are less applicable until the company generates positive cash flows and sales volume. Regarding trading range volatility, the 52-week high is $31.82 and the 52-week low is $10.60. Without a specific current share price provided in the source facts to calculate the exact percentage deviation, the asset trades within a range defined by these historical extremes. The beta value is 0.27, which means the stock price exhibits significantly lower volatility relative to the broader market, moving less than one-third as much as the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is currently in a development phase where historical growth rates cannot be calculated from the available data. Because the growth rates are unavailable, a direct comparison of earnings growth versus revenue growth to determine efficiency is not possible based on the provided facts. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, as these metrics are listed as N/A and 0.0% respectively. This absence of dividend payments signifies that the company reinvests all available earnings and cash reserves back into research, development, and clinical trials to advance its product candidates. The overall growth and income profile is characterized by a focus on capital appreciation through asset expansion rather than current income distribution or historical growth rate expansion.